康方生物(09926.HK)曾續挫逾7%失配股價 擬配股淨籌5.77億元
康方生物-B(09926.HK)擬折讓7%配股淨籌約5.77億元,該股繼本周三升至28.55元創逾五個位遇阻後,掉頭連跌第二天,今早續挫7.3%報24.2元即市低位,成交達625萬股,已接近昨日全日成交量688萬股。
公司公布,與配售代理訂立協議,擬以每股24.27元向不少於六名承配人合共配售2,400萬股新股(佔公司擴大後股本約2.85%),預計配股所得款項淨額約5.77億元,將於明年底前悉數動用,主要用作研發營銷藥物等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.